0.14Open0.14Pre Close0 Volume16 Open Interest7.00Strike Price0.00Turnover673.12%IV20.79%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.14Extrinsic Value100Contract SizeAmericanOptions Type-0.1354Delta0.1173Gamma61.86Leverage Ratio-0.5459Theta0.0000Rho-8.38Eff Leverage0.0006Vega
Annovis Bio Stock Discussion
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
Annovis Bio Inc. (NYSE: ANVS) has announced promising early research results for its lead drug, buntanetap, in combination with other approved drugs for Alzheimer's disease (AD) treatment. While recent FDA-approved drugs like Leqembi and Kisunla may slow cognitive decline in AD patients, they do not improve cognition. Similarly, GLP-1 drugs, origi...
Larger Image: tradingview.com...
$ANVS
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
Annovis Bio Inc. (NYSE: ANVS) has filed three new patents for innovative combination therapies involving its lead compound, buntanetap. These patents cover combinations of buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), or a combination of all three, aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's.
Recent preclinical studies ...
No comment yet